Surface Oncology (SURF) Gets a Buy Rating from JonesTrading

JonesTrading analyst Soumit Roy maintained a Buy rating on Surface Oncology (SURFResearch Report) today and set a price target of $18.00. The company’s shares closed last Friday at $6.37, close to its 52-week low of $4.95.

According to, Roy is a 5-star analyst with an average return of 34.8% and a 46.4% success rate. Roy covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Monopar Therapeutics Inc, and Adaptimmune Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surface Oncology with a $15.60 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $14.40 and a one-year low of $4.95. Currently, Surface Oncology has an average volume of 724.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.